When should the Xpert MTB/RIF (GeneXpert) assay be used for suspected pulmonary tuberculosis, and how should its results—including detection of rifampicin resistance—be interpreted and managed?

Xpert MTB/RIF (GeneXpert) for Tuberculosis

Xpert MTB/RIF should replace sputum microscopy as the initial diagnostic test for suspected pulmonary tuberculosis when available, particularly in patients at high risk of drug-resistant TB, HIV-positive individuals, and those with smear-negative disease. 1

When to Use GeneXpert

Initial Testing Strategy

For patients with cough and suspected pulmonary TB at low risk of drug resistance:

• Use Xpert MTB/RIF as the initial test instead of sputum microscopy 1
• Perform chest x-ray when feasible and resources allow 1
• Collect three sputum specimens (using sputum induction with hypertonic saline if necessary) 2

For patients at high risk of drug-resistant TB (prior TB treatment, contacts of drug-resistant cases, or living in high-prevalence areas):

• Xpert MTB/RIF should replace sputum microscopy as the initial test 1
• Critically important: Also perform sputum mycobacterial cultures and drug susceptibility testing alongside Xpert 1
• Chest x-rays should be performed when feasible 1

Diagnostic Performance

The test demonstrates excellent accuracy across multiple studies:

For pulmonary TB detection:

• Overall sensitivity: 90.7% (88.2-92.7%) and specificity: 94.8% (92.8-96.3%) 3
• In a population of 1000 patients where 100 have TB, Xpert will miss 9 cases and incorrectly diagnose 47 patients 3

Critical performance variations by patient subgroup:

• Smear-positive TB: 98% sensitivity 4 - nearly perfect detection
• Smear-negative TB: 80.7% sensitivity 3 - still superior to microscopy alone
• HIV-positive patients: 87.7% sensitivity 3 - lower than HIV-negative but still valuable
• History of prior TB: 84.8% sensitivity and only 86.2% specificity 3 - significant false-positive risk

Compared to sputum microscopy: Xpert increases TB detection among culture-confirmed cases by 23% 4

Interpreting Results

Tuberculosis Detection

Positive Xpert result:

• Initiate standard four-drug therapy immediately: isoniazid, rifampin, pyrazinamide, and ethambutol 2
• If rifampicin resistance detected, see management below
• Continue treatment pending culture confirmation

Negative Xpert result:

• Do not exclude TB based on a single negative test, especially with moderate-to-high clinical suspicion 5
• Consider repeat testing or bronchoscopy with bronchoalveolar lavage 2
• If clinical suspicion remains high, initiate empirical four-drug therapy 2
• Pursue alternative diagnoses while awaiting culture results 2

Trace-Positive Results (Xpert Ultra)

Common pitfall: Trace-positive results occur in 3.0-30.4% of tests 6

• Only 38.8% of trace-positive results represent true TB 3
• Higher false-positive rate in patients with prior TB history 3
• Consider clinical context, radiographic findings, and history of TB treatment
• Repeat testing may be needed, though data on accuracy of repeat testing remain insufficient 6

Rifampicin Resistance Detection

Test Performance

Excellent accuracy for rifampicin resistance:

• Sensitivity: 95.8% (93.2-97.4%) and specificity: 98.3% (97.0-99.0%) 3
• In a population of 1000 where 100 have rifampicin resistance, Xpert will miss 4 cases and incorrectly identify 16 as resistant 3

Superior to phenotypic testing for borderline mutations:

• Xpert detects 84.2% of borderline rpoB mutations versus only 43.9-57.9% by conventional drug susceptibility testing 7

Management of Rifampicin Resistance

When Xpert detects rifampicin resistance:

In high-prevalence settings (>15% MDR-TB prevalence):

• Positive predictive value is high - treat as MDR-TB 8
• Immediately consult TB specialist or specialized treatment center 2
• Initiate expanded regimen with fluoroquinolone, injectable agent, and additional oral drugs 2
• Never add a single drug to a failing regimen 2

In low-prevalence settings:

• Confirm with culture-based drug susceptibility testing or MTBDRplus 9
• Positive predictive value is lower due to low baseline prevalence 9
• Still initiate expanded therapy while awaiting confirmation if patient is seriously ill 2

Standard approach for confirmed rifampicin resistance:

• Use all-oral bedaquiline-containing shorter regimen (preferred for eligible patients) 10
• Longer regimens required for: pregnant women (ethionamide contraindicated), extensive disease, prior drug exposure, or fluoroquinolone resistance 10
• Perform drug susceptibility testing for fluoroquinolones - essential for regimen selection 10

Critical Caveats

Indeterminate rifampicin results:

• Xpert Ultra produces more indeterminate results (7.6%) compared to Xpert MTB/RIF (0.8%) 6
• Repeat testing with fresh specimen if indeterminate result obtained

Culture remains essential:

• Always reserve sufficient specimen for culture 5
• Culture required for: drug susceptibility testing beyond rifampicin, genotyping, and definitive diagnosis 5
• Monthly sputum cultures mandatory during treatment until two consecutive negatives 2

Do not use Xpert when clinical suspicion is low:

• Positive predictive value <50% in low-suspicion cases 5
• Risk of unnecessary treatment and patient harm

Environmental and resource requirements:

• Requires stable electricity and appropriate room temperature 8
• Cost considerations may limit peripheral-level implementation in low-income countries 8
• Consider referral to higher-level laboratories if local capacity insufficient